Sodium Iodide I 131

CHEMBL1201084 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
153.9 g/mol
LogP
Phase
4

Sodium iodide I-131 is a beta and gamma-emitting radioactive iodine used therapeutically for ablation of normal thyroid remnants post-thyroidectomy, treatment of differentiated thyroid cancer metastases, and hyperthyroidism, as well as diagnostically for thyroid cancer staging. The thyroid's avid uptake of iodide concentrates the radioactive iodine-131, where beta emissions deliver targeted radiation to destroy thyroid tissue. It is a cornerstone of differentiated thyroid cancer management following surgery.

分子量

153.8959 g/mol

TPSA

0.00 Ų

治疗领域

作用机制

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[131I-].[Na+]

InChI

InChI=1S/HI.Na/h1H;/q;+1/p-1/i1+4;

Molecular Formula

INa

HBD / HBA

- / 1

可旋转键数

0

重原子数

2

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Sodium iodide I-131 is a beta and gamma-emitting radioactive iodine used therapeutically for ablation of normal thyroid remnants post-thyroidectomy, treatment of differentiated thyroid cancer metastases, and hyperthyroidism, as well as diagnostically for thyroid cancer staging. The thyroid's avid uptake of iodide concentrates the radioactive iodine-131, where beta emissions deliver targeted radiation to destroy thyroid tissue. It is a cornerstone of differentiated thyroid cancer management following surgery.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Sodium Iodide I 131 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201084. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71368. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.